Resminostat
CAS: 864814-88-0
Ref. 3D-FR138825
| 1mg | To inquire | ||
| 2mg | To inquire | ||
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire |
Product Information
- (2E)-3-[1-({4-[(Dimethylamino)methyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-hydroxyacrylamide
- (E)-3-[1-[[4-[(Dimethylamino)methyl]benzene]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxyacrylamide
- 4SC 201
- (2E)-3-[1-[[4-[(Dimethylamino)methyl]phenyl]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-2-propenamide
- 2-Propenamide, 3-[1-[[4-[(dimethylamino)methyl]phenyl]sulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-, (2E)-
Resminostat is a small molecule that inhibits the transcriptional co-activator, pd-l1. It has been shown to be very effective at reducing the growth of squamous cell carcinoma cells in vitro and in vivo. Resminostat also reduces liver fat content and steatosis by inhibiting fatty acid synthesis. Resminostat has been shown to induce apoptosis in cancer cells through inhibition of nuclear DNA replication, which leads to decreased production of proteins required for cell division. This drug has not been tested on humans but is being investigated as a potential treatment for hepatic steatosis, a condition characterized by excess fat accumulation in the liver.
Chemical properties
Technical inquiry about: 3D-FR138825 Resminostat
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
